Öz
Amaç: Bu çalışmada
değişik maligniteleri olan non-Hodgkin lenfoma, Hodgkin lenfoma, akut lenfositer lösemi, akut myelositer
lösemi, multipl myelom, kronik myelositer lösemi hastalarında HHV-8 IgM ve IgG pozitiflik
oranlarının karşılaştırılması amaçlandı.
Gereç ve Yöntem: Çalışmaya 50 maligniteli hasta
ile 8 sağlıklı birey olmak üzere 58 kişi dahil edildi. Hasta ve kontrol
grubunda HHV-8 IgM ve HHV-8 IgG antikorları indirekt floresan antikor
yöntemiyle araştırıldı. İstatistiksel analizler SPSS programı kullanılarak
yapıldı. İstatistiksel değerlendirmede Fisher’in
Kesin Ki-kare testleri kullanıldı. İstatistiksel olarak p<0,05 değerleri
anlamlı kabul edildi.
Bulgular:
Maligniteli hastalarda HHV-8 IgM antikor
pozitifliği %20 (10/50) oranında saptanırken, kontrol grubunda HHV-8 IgM pozitifliği saptanmadı. Maligniteli
hastalarda HHV-8 IgG pozitifliği %56 (28/50) oranında saptanırken, kontrol
grubunda ise %50 (10/16) oranında
saptandı. HHV-8 IgM pozitifliği hasta grubunda kontrol grubuna göre
istatistiksel olarak anlamlı oranda yüksekti. HHV-8 Ig M pozitifliği en fazla AML saptanırken, HHV-8 IgG pozitifliği en
fazla MM hastalarında saptandı.
Sonuç:
Maligniteli hastalarda saptadığımız
HHV-8 IgM ve HHV-8 IgG pozitiflikleri reaktivasyon veya reenfeksiyonla
ilişkili olabilir. HHV-8 virüsünün maligniteli hastalardaki klinik öneminin
belirlenebilmesi için farklı maligniteleri olan daha fazla sayıda olguyla
yapılacak ve virüs DNA’sının da moleküler yöntemlerle (PZR vb.) araştırıldığı
başka çalışmalara gereksinim olduğu görüşündeyiz.
Anahtar Kelimeler
Kaynakça
- 1. Friborg J, Kong WP, Flowers CC, et al. Distinct biology of Kaposi’s sarcoma-associated herpesvirus from primary lesions and body cavity lymphomas. J Virol 1992; 72: 10073-82.
- 2. Albertı LD, Porter SR, Piateli A, Scully CM, Teo CG . Human herpesvirus 8 and sarcodiosis. The Lancet 1998; 351: 1589-90.
- 3. Zhang XQ, Fıtzpatrıck L, Campbell TB, et al. Comprasion of prevalence of antibodies to human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus) in Brazil and Colorado. J Infect Dis 1998; 178: 1488-91.
- 4. Tisdale JF, Stewart AK, Dickstein B, et al. Molecular and serological examination of the relationship of human herpesvirus 8 to multiple myeloma: orf sequences in bone marrow stroma are not restricted to myeloma patients and other regions of the genome are not detected. Blood 1998; 92: 2681-7.
- 5. Tedeschi R, Paoli PD, Schulz TF, Dillner J. human serum antibodies to a major defined epitope of human herpesvirus 8 small viral capsid antigen. J Infect Dis1999; 179: 1016-20.
- 6. Gessain A, Mauclere P, Beveren MV, et al. Human herpesvirus 8 primary infection occurs during childhood in Cameron, Central Africa. Int J Cancer 1999; 81: 189-92.
- 7. Alhuqayl AA, Shakoor Z, Almogren A, Sghiri R, Hasanato R, Abdulaziz R. Clinical profile of Saudi patients with multiple myeloma. J Nature Sci Med 2019; Vol: XX¦ Iss; XX¦ Month, 2.
Öz
Objective:
The purpose of this study is to compare the HHV-8 IgM and IgG positivity rates
in patients with different malignancies, including non-Hodgkin lymphoma,
Hodgkin’s lymphoma, acute lymphocytic leukemia, acute myelocytic leukemia,
multiple myeloma, and chronic myelocytic leukemia.
Material and Method: Totally
58 individuals, fifty patients with malignancies and eight healthy individuals
were included in the study. Indirect fluorescent antibody
method was used to analyze HHV-8 IgM and HHV-8 IgG antibodies in patient and
control groups. Statistical analysis was conducted with SPSS software.
Fischer’s Exact Ki-kare test and the Mann-Whitney U-test were used in the
statistical evaluation. P values ≤0.05 were
considered statistically significant.
Findings: In
the patient group, 20% of the patients (10/50) were HHV-8 IgM positive. On the
other hand, none of the individuals in the control group were HHV-8 IgM
positive. In the patient group, 56% of the patients (28/50) were HHV-8 IgG
positive, whereas 50% of the individuals (8/16) in the control group were HHV-8
IgG positive. HHV-8 IgM positivity was significantly higher in the patient
group when compared to the control group. The highest level of HHV-8 IgM
positivity was detected in AML patients, whereas MM patients had the highest
level of HHV-8 IgG positivity.
Conclusion:
HHV-8 IgM and HHV-8 IgG positivity in patients with malignancies can be
associated with reactivation or reinfection. Further clinical studies should be
carried out on higher number of patients with different malignancies to
identify the clinical significance of HHV-8 in these patients.
Anahtar Kelimeler
Malignancy HHV-8 IgM IgG indirect fluorescent antibody method
Kaynakça
- 1. Friborg J, Kong WP, Flowers CC, et al. Distinct biology of Kaposi’s sarcoma-associated herpesvirus from primary lesions and body cavity lymphomas. J Virol 1992; 72: 10073-82.
- 2. Albertı LD, Porter SR, Piateli A, Scully CM, Teo CG . Human herpesvirus 8 and sarcodiosis. The Lancet 1998; 351: 1589-90.
- 3. Zhang XQ, Fıtzpatrıck L, Campbell TB, et al. Comprasion of prevalence of antibodies to human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus) in Brazil and Colorado. J Infect Dis 1998; 178: 1488-91.
- 4. Tisdale JF, Stewart AK, Dickstein B, et al. Molecular and serological examination of the relationship of human herpesvirus 8 to multiple myeloma: orf sequences in bone marrow stroma are not restricted to myeloma patients and other regions of the genome are not detected. Blood 1998; 92: 2681-7.
- 5. Tedeschi R, Paoli PD, Schulz TF, Dillner J. human serum antibodies to a major defined epitope of human herpesvirus 8 small viral capsid antigen. J Infect Dis1999; 179: 1016-20.
- 6. Gessain A, Mauclere P, Beveren MV, et al. Human herpesvirus 8 primary infection occurs during childhood in Cameron, Central Africa. Int J Cancer 1999; 81: 189-92.
- 7. Alhuqayl AA, Shakoor Z, Almogren A, Sghiri R, Hasanato R, Abdulaziz R. Clinical profile of Saudi patients with multiple myeloma. J Nature Sci Med 2019; Vol: XX¦ Iss; XX¦ Month, 2.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Araştırma Makalesi |
| Yazarlar | |
| Yayımlanma Tarihi | 22 Eylül 2019 |
| Yayımlandığı Sayı | Yıl 2019 Cilt: 1 Sayı: 4 |
Kaynak Göster
Interuniversity Board (UAK) Equivalency: 1b [Original research article published in journals scanned by international field indexes (included in indices other than the ones mentioned in 1a) - 10 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
| |
|
Journal is indexed in;
Crossref (DOI), Google Scholar, EuroPub, Directory of Research Journal İndexing (DRJI), Worldcat (OCLC), General Impact Factor, OpenAIRE, ASOS Index, ROAD, Turkiye Citation Index, Turk Medline.
Ulakbim-TR Dizin, Index Copernicus, EBSCO, DOAJ is under evaluation.
Journal articles are evaluated as "Double-Blind Peer Review"
.
There is no charge for sending articles, submitting, evaluating and publishing.
Assoc Prof Dr Muhammed KIZILGÜL was qualified as an Associated Editor in ACMJ on 15/02/2020,
Assoc. Prof. Dr. Ercan YUVANÇ leaved, Assoc. Prof. Dr. Alpaslan TANOĞLU became the Editör in Chief in ACMJ on 13/05/2020.